Risk Factors for Carbapenem-Resistant Pseudomonas aeruginosa, Zhejiang Province, China.

Yan-Yan Hu, Jun-Min Cao, Qing Yang, Shi Chen, Huo-Yang Lv, Hong-Wei Zhou, Zuowei Wu, Rong Zhang
Author Information

Abstract

Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a public health concern worldwide, but comprehensive analysis of risk factors for CRPA remains limited in China. We conducted a retrospective observational study of carbapenem resistance in 71,880 P. aeruginosa isolates collected in Zhejiang Province during 2015-2017. We analyzed risk factors for CRPA, including the type of clinical specimen; the year, season, and region in which it was collected; patient information, including age, whether they were an outpatient or inpatient, and whether inpatients were in the intensive care unit or general ward; and the level of hospital submitting isolates. We found CRPA was more prevalent among isolates from patients >60 years of age and in inpatients, especially in intensive care units. In addition, specimen types and seasons in which they were collected were associated with higher rates of CRPA. Our findings can help hospitals reduce the spread of P. aeruginosa and optimize antimicrobial drug use.

Keywords

References

  1. Antimicrob Agents Chemother. 2015 May;59(5):2914-7 [PMID: 25691651]
  2. Antimicrob Resist Infect Control. 2018 Jul 4;7:79 [PMID: 29997889]
  3. Front Microbiol. 2011 Apr 05;2:65 [PMID: 21747788]
  4. EBioMedicine. 2017 May;19:98-106 [PMID: 28479289]
  5. Lancet Infect Dis. 2017 Apr;17(4):390-399 [PMID: 28139431]
  6. Clin Microbiol Rev. 2017 Apr;30(2):557-596 [PMID: 28275006]
  7. Clin Infect Dis. 2017 Jul 1;65(1):158-161 [PMID: 28329350]
  8. Lancet Infect Dis. 2017 Jun;17(6):577 [PMID: 28555574]
  9. MMWR Morb Mortal Wkly Rep. 2018 Apr 06;67(13):396-401 [PMID: 29621209]
  10. Antimicrob Agents Chemother. 2019 Jan 29;63(2): [PMID: 30530598]
  11. Infect Chemother. 2013 Jun;45(2):194-201 [PMID: 24265967]
  12. Clin Microbiol Infect. 2013 Nov;19(11):E483-9 [PMID: 23795938]
  13. J Hosp Infect. 2004 Jul;57(3):209-16 [PMID: 15236849]
  14. Clin Microbiol Rev. 1993 Oct;6(4):428-42 [PMID: 8269394]
  15. Clin Microbiol Infect. 2012 Oct;18(10):934-40 [PMID: 22784293]
  16. Am J Infect Control. 1998 Oct;26(5):522-33 [PMID: 9795682]
  17. Lancet Infect Dis. 2018 Mar;18(3):318-327 [PMID: 29276051]
  18. J Antimicrob Chemother. 2018 Oct 1;73(10):2777-2781 [PMID: 30010951]
  19. PLoS One. 2015 Oct 06;10(10):e0139995 [PMID: 26440806]
  20. Expert Rev Anti Infect Ther. 2010 Jan;8(1):71-93 [PMID: 20014903]
  21. Lancet Infect Dis. 2016 Feb;16(2):161-8 [PMID: 26603172]
  22. Lancet Infect Dis. 2018 Apr;18(4):358-360 [PMID: 29456042]
  23. Clin Microbiol Rev. 2009 Oct;22(4):582-610 [PMID: 19822890]
  24. West Indian Med J. 2005 Sep;54(4):225-31 [PMID: 16312187]
  25. J Antimicrob Chemother. 2019 May 1;74(5):1425-1429 [PMID: 30649419]

MeSH Term

Adolescent
Adult
Age Factors
Carbapenems
Child
Child, Preschool
China
Cross Infection
Humans
Infant
Infant, Newborn
Microbial Sensitivity Tests
Middle Aged
Pseudomonas Infections
Pseudomonas aeruginosa
Retrospective Studies
Risk Factors
Young Adult
beta-Lactam Resistance

Chemicals

Carbapenems

Word Cloud

Created with Highcharts 10.0.0aeruginosaCRPAPseudomonasriskChinaisolatescollectedfactorsresistancePZhejiangProvinceincludingspecimenagewhetherinpatientsintensivecareantimicrobialCarbapenem-resistantpublichealthconcernworldwidecomprehensiveanalysisremainslimitedconductedretrospectiveobservationalstudycarbapenem718802015-2017analyzedtypeclinicalyearseasonregionpatientinformationoutpatientinpatientunitgeneralwardlevelhospitalsubmittingfoundprevalentamongpatients>60yearsespeciallyunitsadditiontypesseasonsassociatedhigherratesfindingscanhelphospitalsreducespreadoptimizedruguseRiskFactorsCarbapenem-ResistantCarbapenembacteriamultidrug-resistantfactorsurveillance

Similar Articles

Cited By